Lunit vs Qure AI (2026)
The global chest X-ray leaders are separated not by clearance, both grade A on regulatory status, but by what each has chosen to prove. Qure AI holds the broadest chest X-ray regulatory footprint in the market, nine products across X-ray and CT plus the qER neurocritical line, and it is the only chest X-ray computer aided detection device the FDA has cleared with a Predetermined Change Control Plan, meaning models can be updated without a new submission. Lunit's distinction is comparative evidence: more than 100 peer reviewed publications in venues from The Lancet Digital Health to JAMA Oncology, including third party head to head validations against competing commercial products, the kind of direct comparison most vendors avoid. If your failure mode is regulatory coverage across findings and geographies with models that stay current, start with Qure. If your failure mode is proving to a committee how the tool performs against alternatives, start with Lunit. In a category where a 2026 study found sensitivity ranging from 21 to 78 percent across chest X-ray AI vendors, that difference in proof posture is the buying question.
- Third party comparison is your bar: the evidence base includes head to head validations against competing commercial products published in peer reviewed venues, a willingness to be benchmarked this index grades explicitly.
- Publication depth: more than 100 peer reviewed publications spanning The Lancet Digital Health, JAMA Oncology, and Radiology across chest X-ray, mammography, and digital breast tomosynthesis.
- Distribution through hardware: deployment at a reported 3,000 plus institutions in more than 40 countries, partly through imaging OEM relationships, which can ride an existing procurement channel.
- Regulatory breadth decides it: nine products across X-ray and CT including the qER neurocritical line, the broadest chest X-ray regulatory footprint in the market.
- Model currency without resubmission: the only chest X-ray computer aided detection device the FDA has cleared with a Predetermined Change Control Plan, so model updates ship without a new submission.
- Findings coverage on plain film: qXR detects, localizes, and categorizes lung nodules, pneumothorax, and pleural effusion, with setting and specialty coverage graded A on this index.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Lunit and Qure AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Lunit its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Qure AI, Lunit grades higher on AI Governance and Bias Disclosure and EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Qure AI its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Lunit, Qure AI grades higher on several axes, including Model Supply Chain Disclosure, Security Certifications and Trust Center and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Lunit or Qure AI?
On the axes where the AI Health Index separates them, Lunit grades higher on AI Governance and Bias Disclosure and EHR and Interoperability Depth, and Qure AI grades higher on several axes, including Model Supply Chain Disclosure, Security Certifications and Trust Center and Deployment Model and Data Residency. Qure AI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Lunit and Qure AI differ most?
The widest separation the AI Health Index records between Lunit and Qure AI is on AI Governance and Bias Disclosure, where Lunit grades B and Qure AI grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Lunit and Qure AI grade the same?
The AI Health Index grades Lunit and Qure AI the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Lunit and Qure AI not disclosed?
At the last review, at least one of Lunit and Qure AI published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Institution counts and deployment figures are vendor published. Both vendors grade A on regulatory status and clinical evidence in this index, with those grades resting on regulatory filings and peer reviewed publications rather than vendor assertion alone.
The 21 to 78 percent sensitivity range cited in the verdict comes from a 2026 comparative study of chest X-ray AI on lung cancer detection and is cited as a category level finding; this index has not attributed the endpoints of that range to specific vendors. Neither vendor publishes pricing.